A new era in idiopathic pulmonary fibrosis: Considerations for future clinical trials

European Respiratory Journal

Volumn 46, Issue 1, 2015, Pages 243-249

  Collard, Harold R ^a   Bradford, Williamson Z ^b   Cottin, Vincent ^c   Flaherty, Kevin R ^d   King, Talmadge E ^a   Koch, Gary G ^e   Kolb, Martin ^f   Martinez, Fernando J ^g   Montgomery, Bruce ^h   Raghu, Ganesh ⁱ   Richeldi, Luca ^j   Rose, Dan ^k   Wells, Athol U ^l   Brown, Kevin K ^m  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b InterMune   (United States)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e IL   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h Cardeas Pharma   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^k Pulmonary Fibrosis Foundation   (United States)

^l ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^m DEPARTMENT OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ARTICLE; CAUSE OF DEATH; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT SAFETY; PRIORITY JOURNAL; BLOOD; IDIOPATHIC PULMONARY FIBROSIS; METHODOLOGY; PULMONOLOGY; TREATMENT OUTCOME; TRENDS;

BIOLOGICAL MARKER;

BIOMARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PULMONARY MEDICINE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84937437695     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00200614     Document Type: Article

References (42)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
5. Ryerson CJ, Collard HR. Hot off the breath: a big step forward for idiopathic pulmonary fibrosis. Thorax 2014; 69: 791-792.
6. Lederer DJ. Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward. Eur Respir J 2013; 42: 1446-1448.
7. Wilson JW, du Bois RM, King TE Jr. Challenges in pulmonary fibrosis: 8-The need for an international registry for idiopathic pulmonary fibrosis. Thorax 2008; 63: 285-287.
8. Guenther A. The European IPF network: towards better care for a dreadful disease. Eur Respir J 2011; 37: 747-748.
9. Ryerson CJ, Corte TJ, Collard HR, et al. A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J 2014; 44: 273-276.
10. National Cancer Institute. Clinical Trials Programs and Initiatives. www.cancer.gov/clinicaltrials/nctn. Date last accessed: September 24, 2014.
11. National Cancer Institute. NCI Press Release. www.cancer.gov/newscenter/newsfromnci/2014/LungMAPlaunch Date last accessed: September 24, 2014.
12. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. Rockville, Food and Drug Administration, 2012.
13. Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 2014; 43: 1430-1438.
14. Maher TM. Disease stratification in idiopathic pulmonary fibrosis: the dawn of a new era? Eur Respir J 2014; 43: 1233-1236.
15. Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med 2013; 1: 479-487.
16. Koch GG, Davis SM, Anderson RL. Methodological advances and plans for improving regulatory success for confirmatory studies. Stat Med 1998; 17: 1675-1690.
17. Lavori PW, Dawson R. Adaptive treatment strategies in chronic disease. Annu Rev Med 2008; 59: 443-453.
18. Sun H, Davison BA, Cotter G, et al. Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method. Circ Heart Fail 2012; 5: 742-749.
19. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
20. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
21. Malouf MA, Hopkins P, Snell G, et al. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology 2011; 16: 776-783.
22. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641-649.
23. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012; 366: 489-491.
24. Agusti A. The path to personalised medicine in COPD. Thorax 2014; 69: 857-864.
25. Watters LC, King TE, Schwarz MI, et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97-103.
26. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
27. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969.
28. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
29. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
30. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
31. Collard HR, Brown KK, Martinez FJ, et al. Study design implications of death and hospitalization as endpoints in idiopathic pulmonary fibrosis. Chest 2014; 146: 1256-1262.
32. Koch GG, Schwartz TA. An overview of statistical planning to address subgroups in confirmatory clinical trials. J Biopharm Stat 2014; 24: 72-93.
33. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232-2239.
34. Stella GM, Inghilleri S, Pignochino Y, et al. Activation of oncogenic pathways in idiopathic pulmonary fibrosis. Transl Oncol 2014; 7: 650-655.
35. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044-1048.
36. Wells AU, Behr J, Costabel U, et al. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax 2012; 67: 938-940.
37. Ryerson CJ. Risk prediction and end-points in idiopathic pulmonary fibrosis: one step at a time. Eur Respir J 2014; 43: 1237-1239.
38. Saville BR, Herring AH, Koch GG. A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data. Stat Med 2010; 29: 75-85.
39. Saville BR, Koch GG. Estimating covariate-adjusted log hazard ratios in randomized clinical trials using cox proportional hazards models and nonparametric randomization based analysis of covariance. J Biopharm Stat 2013; 23: 477-490.
40. Vancheri C, du Bois RM. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur Respir J 2013; 41: 262-269.
41. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med 1999; 18: 1341-1354.
42. Pocock SJ, Ariti CA, Collier TJ, et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012; 33: 176-182.